Wellington Management Group LLP Trims Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Wellington Management Group LLP trimmed its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,795 shares of the company's stock after selling 8,552 shares during the period. Wellington Management Group LLP owned 0.36% of Tarsus Pharmaceuticals worth $7,574,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 14.8% in the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company's stock valued at $117,117,000 after acquiring an additional 17,839 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock worth $63,499,000 after purchasing an additional 5,565 shares during the period. Geode Capital Management LLC increased its position in Tarsus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company's stock valued at $27,494,000 after acquiring an additional 62,555 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in Tarsus Pharmaceuticals by 28.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company's stock valued at $19,565,000 after purchasing an additional 131,636 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Down 1.0 %

Tarsus Pharmaceuticals stock traded down $0.51 during mid-day trading on Wednesday, reaching $48.61. 59,404 shares of the company were exchanged, compared to its average volume of 679,364. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The business has a fifty day moving average of $47.92 and a 200 day moving average of $47.44. The firm has a market cap of $1.87 billion, a P/E ratio of -12.76 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the transaction, the general counsel now directly owns 58,057 shares of the company's stock, valued at $2,687,458.53. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dianne C. Whitfield sold 2,137 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the sale, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,542 shares of company stock valued at $1,581,173. Corporate insiders own 8.25% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Guggenheim restated a "buy" rating and issued a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Barclays decreased their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.